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Abstract. 
 
As a rule, hepatocyte growth factor/scatter 
factor (HGF/SF) is produced by mesenchymal cells, 
while its receptor, the tyrosine kinase encoded by the 
 
met
 
 proto-oncogene, is expressed by the neighboring 
epithelial cells in a canonical paracrine fashion. In the 
present work we show that both HGF/SF and 
 
met
 
 are 
coexpressed by undifferentiated C2 mouse myoblasts. 
In growing cells, the autocrine loop is active as the re-
ceptor exhibits a constitutive phosphorylation on ty-
rosine that can be abrogated by exogenously added 
anti-HGF/SF neutralizing antibodies. The transcription 
of 
 
HGF
 
/
 
SF
 
 and 
 
met
 
 genes is downregulated when myo-
blasts stop proliferating and differentiate. The coex-
pression of 
 
HGF
 
/
 
SF
 
 and 
 
met
 
 genes is not exclusive to 
C2 cells since it has been assessed also in other myo-
genic cell lines and in mouse primary satellite cells, sug-
gesting that HGF/SF could play a role in muscle devel-
opment through an autocrine way.
To analyze the biological effects of HGF/SF receptor 
activation, we stably expressed the constitutively acti-
vated receptor catalytic domain (p65
 
tpr-met
 
) in C2 cells. 
This active kinase determined profound changes in cell 
shape and inhibited myogenesis at both morphological 
and biochemical levels. Notably, a complete absence of 
muscle regulatory markers such as MyoD and myoge-
nin was observed in p65
 
tpr-met
 
 highly expressing C2 
clones. We also studied the effects of the ectopic ex-
pression of human isoforms of 
 
met
 
 receptor (h-
 
met
 
) and 
of HGF/SF (h-HGF/SF) in stable transfected C2 cells. 
Single constitutive expression of h-
 
met
 
 or h-HGF/SF 
does not alter substantially the growth and differentia-
tion properties of the myoblast cells, probably because 
of a species-specific ligand–receptor interaction. A C2 
clone expressing simultaneously both h-
 
met
 
 and 
h-HGF/SF is able to grow in soft agar and shows a de-
crease in myogenic potential comparable to that pro-
moted by p65
 
tpr-met
 
 kinase. These data indicate that a 
 
met
 
 kinase signal released from differentiation-depen-
dent control provides a negative stimulus for the onset 
of myogenic differentiation.
 
C
 
onsiderable 
 
evidence has been accumulated indi-
cating the importance of hepatocyte growth factor
(HGF)
 
1
 
 in liver physiology (for review see Micha-
lopoulos and Zarnegar, 1992). This protein is a potent mi-
togen for mature hepatocytes in primary culture (Miya-
zawa et al., 1989; Nakamura et al., 1989) and functions in
vivo as a hepatotrophic factor during the regenerative events
in the liver injured by a partial hepatectomy or by hepato-
toxin treatment (Ishiki et al., 1992). In addition, mice lack-
ing HGF exhibit severe impairment in liver development
and die in utero (Schmidt et al., 1995). Although its role in
maintaining liver homeostasis is well accepted, other stud-
ies have shown that HGF is a multifunctional cytokine
possessing a wide spectrum of biological activities besides
the hepato-specific ones by which it was first identified
(for review see Goldberg and Rosen, 1993). HGF has been
reported to stimulate proliferation of endothelial cells and
various epithelial cells, including melanocytes and kerati-
nocytes (Igawa et al., 1991; Kan et al., 1991; Matsumoto
et al., 1991; Rubin et al., 1991; Bussolino et al., 1992). The
mitogenicity exerted on renal tubular and on pulmonar
cells reflects the active role of HGF in promoting regener-
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1. 
 
Abbreviations used in this paper
 
: HGF, hepatocyte growth factor;
h-HGF/SF, human HGF/SF; h-
 
met
 
, human isoform of 
 
met
 
 receptor; HS,
horse serum; IGF, insulin-like growth factor; LTR, long terminal repeat;
MHC, myosin heavy chain; MHCe, embryonic MHC; SF, scatter factor.
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ation in kidney (Nagaike et al., 1991; Kawaida et al., 1994)
and lung (Yanagita et al., 1993) upon tissue damage.
Moreover, HGF has been shown to be identical to scat-
ter factor (SF), a fibroblast-derived soluble polypeptide
that disperses cohesive epithelial colonies, increasing cell
motility and invasiveness (Stoker et al., 1987; Gherardi
et al., 1989; Weidner et al., 1990, 1991; Naldini et al.,
1991
 
b
 
). HGF/SF has been also qualified as a morphogen
for its ability to induce the organization of cells into or-
dered tubule-like structures (Montesano et al., 1991; Tsar-
faty et al., 1992); on endothelial cells, the morphogenic
stimulus assumes the character of angiogenesis with for-
mation of blood vessels in vivo (Bussolino et al., 1992;
Grant et al., 1993).
In virtue of its mitogenic, motogenic, and morphogenic
properties, it is believed that HGF/SF could be involved in
many processes where both cell growth and migration are
required, such as embryonal development, tissue repair,
and organ regeneration. This notion is further strength-
ened by the observation that HGF/SF mRNA is detected
in several organs (Tashiro et al., 1990; Zarnegar et al., 1990;
Sonnenberg et al., 1993), and that HGF/SF protein is still
broadly localized by immunohistochemical means (Wolf
et al., 1991; DeFrances et al., 1992). Finally, there is evi-
dence of the involvement of HGF/SF in tumorigenesis and
in tumor progression toward a more aggressive phenotype
(Weidner et al., 1990; Rong et al., 1992, 1994; Bellusci et
al., 1994).
HGF/SF shares structural homologies with plasminogen
(38% amino acid sequence identity) and other blood coag-
ulation serine proteases, although it has no protease activity
(Miyazawa et al., 1989; Nakamura et al., 1989). Similarly
to the biosynthetic pathway of the serine proteases, HGF/
SF is secreted by cells of mesodermal origin as a single-
chain precursor that is then processed to yield a disulfide-
linked complex composed of a heavy and a light chain
(Miyazawa et al., 1989; Nakamura et al., 1989; Weidner et al.,
1990). The proteolytic maturation is serum dependent and
is necessary for the acquisition of biological activity (Hart-
mann et al., 1992; Lokker et al., 1992; Naka et al., 1992;
Naldini et al., 1992, 1995).
The pleiotropic action of HGF/SF is transduced by a sin-
gle transmembrane receptor encoded by the 
 
met
 
 proto-
oncogene (Bottaro et al., 1991; Naldini et al., 1991
 
a
 
,
 
b
 
;
Weidner et al., 1993). The met protein has a heterodimeric
structure consisting of an extracellular 
 
a
 
 subunit (50 kD)
and a membrane-spanning 
 
b
 
 subunit (145 kD) endowed
with a tyrosine kinase domain in its cytoplasmic region.
Both subunits originate from glycosylation and from pro-
cessing of a common precursor of 170 kD (Giordano et al.,
1989
 
a
 
,
 
b
 
).
While its ligand is produced prevalently by stromal cells,
 
met
 
 receptor exhibits a complementary pattern of distri-
bution, with the highest expression levels observed primar-
ily in epithelial cells (Chan et al., 1988; Iyer et al., 1990;
Di Renzo et al., 1991; Prat et al., 1991). Since HGF/SF-
producing and -responding (
 
met
 
-positive) cells belong to
adjacent tissue compartments, HGF/SF is actually consid-
ered a major paracrine mediator of mesenchyme–epithe-
lium interactions (Sonnenberg et al., 1993; Comoglio and
Boccaccio, 1996).
HGF/SF binding triggers 
 
met
 
 kinase activation and its
autophosphorylation on specific tyrosine residues that will
represent docking sites for multiple transductional pro-
teins (Ponzetto et al., 1994). It is thought that the particu-
lar cellular response (cell growth vs cell locomotion or mor-
phogenesis) may be ensured by the integration of distinct
signaling pathways into different cell types. Recent studies
have shown an active role of HGF/SF in the control of mus-
cle development (Bladt et al., 1995; Maina et al., 1996; Taka-
yama et al., 1996; Yang et al., 1996).
In this study we have examined the expression of HGF/
SF and its receptor in in vitro mouse muscle cells so as to
determine whether HGF/SF might be implicated in myo-
genesis. In C2 myoblasts, we have detected the presence of
transcripts specific for both the receptor and its ligand.
The synthesis of the corresponding protein products has
also been demonstrated. The hypothesis that HGF/SF
could be an autocrine factor for C2 myoblasts has been
confirmed by the observation that its cognate receptor is
highly tyrosine phosphorylated and that this phosphoryla-
tion is inhibited by an anti-HGF/SF neutralizing antibody.
Moreover, the finding that other myogenic cell lines and
primary satellite cell cultures coexpress both HGF/SF and
 
met
 
 receptor supports a broader physiological relevance of
this growth factor in muscle development.
The expression of both murine 
 
met
 
 and 
 
HGF
 
/
 
SF
 
 genes
was found to be downregulated in concomitance with C2
myogenic differentiation. In fact, we observed a coordinate
transcriptional repression during the transition from pro-
liferating myoblasts to differentiated myotubes. Such in-
teresting behavior of endogenous genes prompted us to in-
vestigate the consequences of a constitutive 
 
met
 
 activation.
Here we show that the expression of p65
 
tpr
 
-
 
met
 
 kinase
(Cooper et al., 1984; Park et al., 1986; Gonzatti-Haces et al.,
1988; Rodriguez and Park, 1993) results in substantial al-
terations of cell growth and inhibition of myogenesis, as
does the constitutive activation of the human isoform of
 
met
 
 receptor (h-
 
met
 
) through a species-specific autocrine
stimulation by human HGF/SF (h-HGF/SF).
 
Materials and Methods
 
Cell Cultures
 
Cells of the mouse myogenic C2 cell line (Yaffe and Saxel, 1977) clone 7
and of the mouse teratocarcinoma-derived myogenic PCD2 cell line
(Boon et al., 1974) were maintained as undifferentiated myoblasts in
DME supplemented with 20% FCS in a 10% CO
 
2
 
 atmosphere. To induce
cell differentiation, myoblasts were grown to confluence, and then shifted
to DME supplemented with 0.5–2% FCS or 10% horse serum (HS). Ex-
tensive morphological and biochemical differentiation was obtained after
24–48 h. Mouse primary satellite cells (kindly provided by Dr. Giulio
Cossu, Institute of Histology, University of Rome “La Sapienza,” Roma,
Italy) were derived from limbs of 14-d-old mice, purified according to Sal-
vatori et al. (1993) and amplified once.
C3H-10T1/2 mouse embryonic fibroblasts and HepG2 human hepato-
carcinoma cells (used as positive control for the expression of 
 
met
 
 recep-
tor in Northern and Western blot experiments) were cultured in 10%
FCS-containing DME. C3H-10T1/2-MyoD is a C3H-10T1/2 subclone sta-
bly expressing the myogenic determinant MyoD (Davis et al., 1987). The
epithelial cell lines (MDCK and mouse liver progenitor) used in the scat-
ter assay are described below.
Agar selection was carried out by seeding 10
 
3
 
 or 10
 
4
 
 cells per 60-mm-
diam dish in DME containing 5% FCS and 0.35% Bacto-Agar (Difco
Laboratories, Detroit, MI) and layering this suspension in quadruplicate
onto a base of 0.7% agar. 
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Indirect Immunofluorescence Staining
 
Cells grown on glass coverslips were fixed by immersion in methanol-
acetone (3:7 vol/vol) for 15 min at 
 
2
 
20
 
8
 
C and then air dried. Coverslips
were then incubated at 37
 
8
 
C in a humidified atmosphere with the primary
antibody, in some cases diluted in PBS containing 1% BSA. After three
washes with PBS, the coverslips were incubated with the secondary fluo-
rochrome-conjugated antibody diluted in PBS plus 1% BSA, washed re-
peatedly with PBS, and mounted with 70% glycerol in PBS.
To detect the embryonic myosin heavy chain (MHCe), we used the
mouse mAb MF20 (Bader et al., 1982) as undiluted hybridoma superna-
tant. As secondary antibody, we used a goat anti–mouse IgG rhodamine-
conjugated IgG fraction (Cappel Immunochemical Products, Malvern,
PA) diluted 1:100.
 
Plasmids and Probes
 
The expression vectors used in the transfection assay were: (
 
a
 
) pRK5-
 
met
 
,
in which the entire coding sequence of human 
 
met
 
 receptor is cloned un-
der the control of the cytomegalovirus promoter; (
 
b
 
) pPEB-HGF/SF, con-
taining the full-length human HGF/SF cDNA cloned downstream of the
murine sarcoma virus LTR; and (
 
c
 
) pMT2-
 
tpr-met
 
, in which the human
 
tpr-met
 
 cDNA is cloned downstream of the adenovirus late promoter
(Ponzetto et al., 1994). As selectable markers for stably transfected cells,
we used plasmids: (
 
a
 
) pRSV-
 
neo
 
, containing the neomycin resistance gene
under the control of the Rous Sarcoma virus long terminal repeat (LTR)
(Mulligan and Berg, 1980); (
 
b
 
) pSV2-hygro, containing the hygromycin re-
sistance gene under the control of the SV-40 promoter-enhancer region
(Maione et al., 1992); and (
 
c
 
) pBABE-puro, containing the puromycin re-
sistance gene under the control of Moloney murine leukemia virus LTR
(Morgenstern and Land, 1990).
For Northern blot hybridization experiments, probes were labeled with
 
a
 
[
 
32
 
P]dATP by the random priming method. To detect specific transcripts,
the following probes were used: (
 
a
 
) the human full-length 
 
met
 
 cDNA
(Ponzetto et al., 1991); (
 
b
 
) the human full-length HGF/SF cDNA (Naldini
et al., 1991); (
 
c
 
) the plasmid pMHC 2.2, specific for MHCe transcript
(Weydert et al., 1985); (
 
d
 
) the EcoRI fragment from plasmid pEMC11s
specific for MyoD transcript (Davis et al., 1987); and (
 
e
 
) the human cDNA
myf4 (Braun et al., 1989) highly homologous to the mouse myogenin tran-
script, provided by Dr. Hans Henning Arnold (University of Hamburg
Medical School, Hamburg, Germany).
 
Cell Transfections
 
Cells were transfected by the calcium phosphate precipitation method
(Wigler et al., 1977), with 
 
z
 
10
 
5
 
 cells per 60-mm-diam dish. Single stable
transfectants were obtained by cotransfecting each dish with the following
amounts of DNA: 5 
 
m
 
g of the expression vector and 0.5 
 
m
 
g of the selection
plasmid. For h-
 
met
 
/h-HGF/SF double transfections, 2.5 
 
m
 
g of pRK5-
 
met
 
plasmid, 2.5 
 
m
 
g of pPEB-HGF/SF plasmid, and 0.5 
 
m
 
g of pRSV-
 
neo
 
 plas-
mid were used.
2 d after transfection, cells were split 1:7 in selective medium. As re-
quired, 400 
 
m
 
g/ml G418, 200 
 
m
 
g/ml hygromycin, or 1 
 
m
 
g/ml puromycin was
used. The medium was changed every 2–3 d and, after 10–15 d, the surviv-
ing colonies were isolated and separately amplified.
 
RNA Extraction and Northern Analysis
 
Total RNA was prepared according to the acid guanidinium thiocyanate-
phenol-chloroform single step method as described by Chomczynski and
Sacchi (1987).
For Northern blot analysis, 10–15 
 
m
 
g of each RNA sample was fraction-
ated by electrophoresis through 0.8% agarose gel containing 0.66 M form-
aldehyde and 1
 
3
 
 MOPS buffer (20 mM MOPS, 5 mM NaAc, 1 mM EDTA,
pH 7.0). After running, gel was washed twice in 10
 
3
 
 SSC (1.5 M NaCl,
0.15 M sodium citrate, pH 7.2) for 30 min at room temperature to remove
formaldehyde, and RNAs were transferred to nylon filters (Hybond N;
Amersham Intl., Little Chalfont, UK) by a capillarity fluid of the same
buffer (Sambrook et al., 1989). Filters were fixed by Stratalinker (1,200 
 
m
 
J 
 
3
 
100). Prehybridization and hybridization were carried out at 42
 
8
 
C using
the commercial Hybrisol solution (Oncor, Gaithersburg, MD). 
 
a
 
-[
 
32
 
P]-
dATP-labeled probes were used at a 2 
 
3
 
 10
 
6
 
 counts per ml concentration.
Hybridized filters were washed once at 42
 
8
 
C in a 2
 
3
 
 SSPE (a 20
 
3
 
 SSPE
solution was 3 M NaCl, 200 mM NaH
 
2
 
PO
 
4
 
?
 
H
 
2
 
O, 20 mM EDTA, pH 7.4),
0.1% SDS solution, and twice at 60
 
8
 
C in a 1
 
3
 
 SSPE, 0.1% SDS solution.
Finally, filters were exposed to an autoradiographic film (Fuji Photo Film
Co., Tokyo, Japan) at 
 
2
 
70
 
8
 
C with intensifying screens for variable peri-
ods.
Comparative quantitation of RNAs was estimated by staining the gel
with ethidium bromide and rehybridizing the filters with a probe for a
constitutively expressed gene (
 
GAPDH
 
) (glyceraldehyde-3-phosphate-
dehydrogenase) (Piechaczyk et al., 1984).
 
Immunoprecipitation and Western Blotting
 
Subconfluent cell cultures were washed three times in cold PBS and lysed
for 30 min on ice in a buffer containing 50 mM Tris-Cl pH 7.5, 150 mM
NaCl, 10% glycerol, 5 mM EGTA, pH 7.5, 50 mM NaF, pH 8, 1.5 mM
MgCl
 
2
 
, 1% (vol/vol) Triton X-100, supplemented with various protease
and phosphatase inhibitors (leupeptin, aprotinin, PMSF, sodium-ortho-
vanadate). After clearing by centrifugation at 15,000 rpm for 20 min at
4
 
8
 
C, the protein content of samples was quantified by the Biorad method.
Equal amounts of cellular extracts were pretreated with 50 
 
m
 
l protein
A–Sepharose (Pharmacia, Uppsala, Sweden) (50% vol/vol in PBS 
 
1
 
 3%
BSA) to remove nonspecific binding, and then incubated for 1 h at 4
 
8
 
C
with anti-
 
met
 
 antibodies. The following antibodies were used: (
 
a
 
) rabbit
anti–h-
 
met
 
 antiserum (C-12 antibody) and (
 
b
 
) rabbit anti–m-
 
met
 
 antise-
rum (SP260 antibody), both purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA).
The immunocomplexes were collected by adding 50 
 
m
 
l protein A–Seph-
arose (incubation for 1 h at 4
 
8
 
C) and washed four times with NET-gel
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40, 1 mM EDTA,
pH 8.0, 0.25% gelatin, 0.02% sodium azide). Finally, the immunocom-
plexes were solubilized in boiling Laemmli buffer containing 5% 
 
b
 
-mer-
captoethanol, electrophoresed on 8–12% SDS polyacrylamide gels, and
transferred onto nitrocellulose filters (Hybond C; Amersham Intl.) by the
semidry blot method.
Western blot analysis was carried out by using the anti-
 
met
 
 polyclonal
antibodies described above or an anti-phosphotyrosine mAb (Upstate Bio-
technology Inc., Lake Placid, NY). The staining of the blots was per-
formed by the enhanced chemiluminescence system (ECL; Amersham
Intl.).
The autocrine mode of action of HGF/SF in C2 cells was investigated
by measuring the degree of tyrosine phosphorylation of 
 
met receptor in
different culture conditions. Briefly, C2 cells were treated for 5 min on ice
with an acid solution (20 mM acetic acid, 150 mM NaCl, 0.25% BSA), and
subsequently incubated with 0.5 M NaCl-containing DME for 20 min at
378C to dissociate HGF/SF molecules from cell surface (Sturani et al., 1988;
Naldini et al., 1992). Then cells were lysed immediately or after an addi-
tional incubation (30 min at 378C) with fresh 10% FCS-containing me-
dium, C2-conditioned medium, or C2-conditioned medium previously in-
cubated with a neutralizing goat antibody directed against mouse HGF/SF
(kindly supplied by Dr. Ermanno Gherardi, Imperial Cancer Research
Fund, Cambridge, UK).
Scatter Assay
The production of HGF/SF by C2 cells and transfected clones was investi-
gated by measuring the ability of the corresponding conditioned medium
to dissociate epithelial MDCK cell colonies (Stoker et al., 1987). The as-
say was performed in 24-well Costar plates (Cambridge, MA). 4,000–6,000
cells per well were plated and exposed to serial dilutions of conditioned
medium in 10% FCS-containing DME for 15–20 h at 378C. After being
fixed with 11% glutaraldehyde and colored with crystal violet, cell scatter-
ing was examined by a phase-contrast light microscope. Scatter activity
was generally detected in the range of 1:30–1:300 dilutions.
To verify the extension of HGF/SF processing, the scatter assay was
performed using mouse liver progenitor cells (Medico et al., 1996), which
can be cultivated in low serum; in this case, the testing conditioned me-
dium was diluted in 1% FCS-containing DME.
Results
Expression of Endogenous met and HGF/SF in 
Myogenic Cells
To determine whether C2 myoblasts could be a potential
target for HGF/SF action, we analyzed the expression ofThe Journal of Cell Biology, Volume 137, 1997 1060
HGF/SF receptor (met) in proliferating cells by Northern
blotting of total RNA. Using the full-length human met
cDNA as a probe, we have detected a transcript of z8.5 kb,
which represents the major met mRNA expressed in mu-
rine tissues and in human hepatocarcinoma (Hep G2) cells
(Fig. 1 A).
Met protein was visualized from C2 cell lysates by im-
munoprecipitation and Western blotting with an anti–
murine  met polyclonal antibody (Fig. 1 B). In this experi-
ment both the 170-kD single chain precursor (p170ab) and
the 145-kD b subunit of met receptor (p145b) were clearly
detected. Furthermore, to establish if met receptor was ac-
tivated in C2 cells, a Western blot with an anti-phosphoty-
rosine mAb was performed on the immunoprecipitated
protein. As shown in Fig. 1 B, p145b exhibits a high degree
of phosphorylation on tyrosine residues, indicating that
met receptor is activated in C2 myoblasts.
To determine if met activation was due to an autocrine
stimulation, the production of HGF/SF by C2 cells was in-
vestigated, since muscle cells belong to the mesenchymal
compartment that is known to be a preferential expression
site of met ligand (Sonnenberg et al., 1993). Northern blot
analysis has brought evidence of the presence of a 6-kb tran-
script (Fig. 2 A) equivalent in size to the principal HGF/SF
mRNA species described by other authors (Nakamura et al.,
1989; Tashiro et al., 1990). The presence of HGF/SF pro-
tein in the supernatant of C2 cells was tested by assaying
its scatter activity on MDCK epithelial cells (Fig. 2 B), in
comparison with the standard medium (Fig. 2 C). Titration
by serial dilutions indicated the production of amounts
comparable to that of HGF/SF-producing fibroblast cells
(Stoker et al., 1987). The existence of a natural autocrine
loop for HGF/SF in C2 myoblasts was confirmed by ex-
posing C2 cell cultures to an acid treatment followed by an
incubation with DME supplemented with 0.5 M NaCl.
These conditions have been shown to effectively dissociate
the ligand–receptor complexes and remove the HGF/SF
molecules linked to extracellular matrix (Sturani et al., 1988;
Naldini et al., 1992). Duplicate plates of C2 cells were
treated in the same way and then further incubated for 30
min with C2-conditioned or fresh 10% FCS-containing me-
dium, respectively. Results shown in Fig. 3 demonstrate
that the treatment causes a net decrease of met tyrosine
kinase phosphorylation and that only C2-conditioned me-
dium restores phosphorylation. Moreover, C2-conditioned
medium loses its capacity to stimulate met kinase if previ-
ously incubated with a neutralizing anti-HGF/SF antibody.
These results demonstrate that met receptor expressed by
C2 myoblasts is activated by the endogenously produced
HGF/SF.
The existence of a natural HGF/SF autocrine loop in C2
cells prompted us to assess if this autocrinia could reflect a
common situation in cells belonging to the myogenic lin-
eage and not represent a peculiarity of C2 myoblasts only.
Therefore, we analyzed the expression of met and HGF/SF
in mouse primary satellite cells and in the PCD2 teratocar-
cinoma-derived mouse cell line, which undergoes myo-
genic differentiation (Boon et al., 1974). By Northern blot
analysis, we have detected specific signals for both the re-
ceptor and its ligand (Fig. 4). Here it should be noted that
primary cultures were double precleared from fibroblasts
to reduce as much as possible any contribution of these
cells to the HGF/SF mRNA signal detected, since HGF/SF
is a main fibroblast-secreted cytokine (Stoker et al., 1987;
Gherardi et al., 1989; Weidner et al., 1990). The persis-
tence of high expression levels of the muscle-specific de-
terminant MyoD confirmed the identity of these cells.
Note that PCD2 cells undergo differentiation in the ab-
sence of MyoD expression, whose function could be re-
placed by other members of the family of myogenic deter-
minants (Weintraub, 1993).
Met and HGF/SF Genes Are Coordinately 
Downregulated during Myogenic Differentiation
Previous works have shown that the expression of differ-
ent genes encoding for growth factors and their cognate
receptors is modulated during myogenesis (Ewton et al.,
1988; Olwin and Hauschka, 1988; Tollefsen et al., 1989a,b;
Hu and Olson, 1990; Lafyatis et al., 1991; Moore et al., 1991).
To learn whether the expression of met and HGF/SF genes
was subjected to quantitative variations during muscle dif-
ferentiation, we have performed a Northern blot analysis
of total RNA prepared from undifferentiated and differ-
entiating C2 cells. Results reported in Fig. 5 show that the
highest level of met and HGF/SF mRNA was found in ac-
Figure 1. Synthesis of met receptor by C2 myoblast cells. (A)
Northern blot of total RNA extracted from human hepatocarci-
noma HepG2 cells and C2 cells probed with human full-length
met cDNA (Ponzetto et al., 1991). The position of 8.5-kb met-
related transcript and the 28S ribosomal RNA is indicated. (B)
Activation state of met receptor expressed by C2 myoblasts. Pro-
tein extracts from proliferating C2 myoblasts were immunopre-
cipitated with anti–met rabbit SP260 antiserum (directed against
the COOH-terminal portion of the murine protein), electro-
phoresed onto 8% reducing SDS-PAGE, and immunoblotted
with SP260 antiserum (a-m-met). In these conditions, both the
145-kD b subunit of mature met receptor (p145b) and the 170-kD
single-chain precursor (p170ab) were detected. The same filter
was stripped and reprobed with monoclonal anti-phosphoty-
rosine antibodies (a-PTyr) to provide evidence for the activation
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tively proliferating myoblasts, cultured in 20% FCS-con-
taining medium. When the myoblasts were induced to dif-
ferentiate by a shift to low mitogen–containing medium (2%
FCS or 10% HS), an evident decrease for both transcripts
was observed. The transcriptional repression is strictly
coupled with the myogenic process since the hybridization
signals are almost undetectable at day 3 postserum depri-
vation, when a consistent number of mature multinucle-
ated myotubes are present. Muscle differentiation was also
assessed by measuring the expression of myosin heavy
chain (MHC) mRNA, whose gene is transcriptionally acti-
vated early in differentiation.
The observation that mRNA decline is differentiation
dependent enables us to infer that the mechanisms respon-
sible for cell growth–arrest and muscle-specific gene acti-
vation can also be involved in the control of both met and
HGF/SF gene expression. To test this hypothesis, we have
analyzed the expression of met and HGF/SF genes in C3H-
10T1/2 mouse fibroblasts, which can be converted to myo-
genic lineage by stable ectopic expression of MyoD (Davis
et al., 1987). As reported in Fig. 5, C3H-10T1/2 cells syn-
thesize both met and HGF/SF mRNAs that are downregu-
lated in low serum only upon myogenic conversion.
Effect of tpr-met Expression in C2 cells
The observation that endogenous met and HGF/SF genes
are coordinately downregulated during myogenic differen-
tiation of C2 cells raises the question if HGF/SF-mediated
signals could exert a negative constraint on muscle differ-
Figure 2. Synthesis of HGF/
SF by C2 myoblast cells. (A)
Northern blot analysis of to-
tal RNA extracted from hu-
man hepatocarcinoma cells
(HepG2) and C2 cells to il-
lustrate the production of a
6-kb HGF/SF mRNA. As
previously reported in litera-
ture (Shiota et al., 1992),
HepG2 cells are negative for
the expression of HGF/SF
gene. (B and C) Phase-con-
trast micrographs of a scat-
ter assay carried out with
MDCK epithelial cells incu-
bated with C2 myoblast–con-
ditioned medium (B) or stan-
dard medium (C).
Figure 3. HGF/SF is an autocrine factor for C2 myoblasts. C2
proliferating cells exposed to culture conditions that remove
HGF/SF molecules from cell surface (see Materials and Meth-
ods) were lysed, immunoprecipitated with anti–murine met anti-
bodies, and analyzed for the tyrosine phosphorylation degree of
HGF/SF receptor by Western blotting with anti-phosphotyrosine
antibodies (a-PTyr). Control cells (lane 1); C2 cells acid treated
and incubated with 0.5 M NaCl-containing DME (lane 2); cells
treated as in lane 2 and further incubated with C2-conditioned
medium (lane 3) or C2-conditioned medium pretreated with an anti-
HGF/SF neutralizing antibody (lane 4); cells as in lane 2 and fur-
ther incubated with fresh 10% FCS-containing medium (lane 5).
Figure 4. Coexpression of met
and HGF/SF in other myogenic
cells. Total RNA from C2 myo-
blasts, PCD2 mouse myoblasts,
and mouse primary satellite
(Sat) cell cultures was hybrid-
ized with the indicated probes.The Journal of Cell Biology, Volume 137, 1997 1062
entiation. To test this hypothesis, we have studied the con-
sequences of the expression of p65tpr-met, a constitutively
activated version of the met kinase (Cooper et al., 1984; Park
et al., 1986; Gonzatti-Haces et al., 1988; Rodriguez and Park,
1993).
C2 cells were transfected with pMT2–tpr-met construct
in which the human tpr-met cDNA is cloned downstream
of the adenovirus late promoter. The construct pBABE-
Puro encoding for the puromycin resistance was used as
a selection marker. 20 puromycin-resistant clones were
isolated, individually amplified, and tested for the pres-
ence of p65tpr-met protein by Western blot analysis. All to-
gether, eight clones resulted to express variable levels of
the heterologous protein and three of them were found to
express high levels of p65tpr-met (clones 2, 5, and 11; Fig.
6 A). In all the positive clones, p65tpr-met was strongly evi-
denced by an anti-phosphotyrosine antibody in a Western
blot performed on the immunoprecipitated protein (Fig.
6 B); this argues for a full activation of p65tpr-met kinase in
transfected myoblast cells. Moreover, the degree of ty-
rosine phosphorylation parallels the protein content. As
expected, kinase activity of p65tpr-met is retained also in
cells grown at a low serum condition (data not shown).
The p65tpr-met highly expressing clones exhibit a singular
cell morphology that is shown in Fig. 7. In detail, cells are
very spindle-shaped and little adherent to the substrate,
implying a profound reorganization of the cytoskeletal
apparatus. This scattered appearance is identical to the mo-
togenic response observed when epithelial cells are stimu-
lated by HGF/SF (see Fig. 2 B). The increase of cell motil-
ity in p65tpr-met highly expressing clones was confirmed by
the Boyden chamber assay (data not shown). The mor-
phology of the clones that express low quantities of p65tpr-met
is comparable to that of C2 parental myoblasts (not
shown).
It has been shown that p65tpr-met promotes cell prolifera-
tion and tumorigenesis (Cooper et al., 1984; Park et al., 1986);
nevertheless, the growth rate of p65tpr-met-expressing clones,
independent from the protein expression levels, is not sig-
nificantly modified in comparison with the C2 parental cell
line (data not shown).
The motogenic properties of p65tpr-met highly expressing
clones are accompanied by a marked inability to differen-
tiate when confluent cultures are deprived of mitogens.
Immunofluorescence staining of MHC protein synthesized
after 48 h of incubation in differentiating medium shows
few MHC-positive cells, which appear as single isolated
and fusiform cells and very sporadically as multinucleated
cells (Fig. 7).
To characterize at a biochemical level the decrease of
myogenic potential of p65tpr-met expressing clones, we in-
vestigated the expression of the muscle-specific regulatory
genes MyoD and myogenin (Weintraub, 1993). In C2 pa-
rental cells, the gene encoding for myogenin is transcrip-
tionally activated in concomitance with the beginning of
muscle differentiation; on the contrary, MyoD gene is ex-
pressed also at the myoblast stage although the protein
product becomes functional only in differentiating condi-
tions. By Northern blot analysis, we have found a com-
plete absence of MyoD and myogenin transcripts in p65tpr-met
highly expressing cells (Fig. 8).
In the p65tpr-met moderate expressing clones, the tran-
scripts for MyoD and myogenin are detectable, but the rel-
ative hybridization signals have an intensity lower than
those of C2 parental cells, suggesting that the degree of
myogenic inhibition correlates with the levels of p65tpr-met
expressed (Fig. 8). Control C2 cells stably transfected with
Figure 5. The expression of met and HGF/SF genes is downregu-
lated concomitantly with the onset of myogenic differentiation. C2,
C3H-10T1/2, and C3H-10T1/2-MyoD cells were cultured in DME
containing 20% FCS up to confluency, and then transferred to
low serum–containing medium (2% FCS). Total RNA extracted
before serum deprivation (lanes 1) and 1 (lanes 2), 2 (lanes 3),
and 3 (lanes 4) d after serum deprivation was assayed for the ex-
pression of met, HGF/SF, and a muscle-specific marker, MHC,
transcripts. Quantitative decrease of met and HGF/SF mRNA syn-
thesis was observed only in the presence of muscle differentiation.
Figure 6. Extensive p65tpr-met kinase activation in p65tpr-met-
expressing C2 clones. Total cell lysates were immunoprecipitated
with rabbit anti–met C12 antiserum (directed against the COOH-
terminal portion of the human protein), electrophoresed onto
12% reducing SDS-PAGE, and immunoblotted with the same
antibody (A) or anti-phosphotyrosine antibodies (B). A good
correlation was found between the p65tpr-met protein levels and its
degree of tyrosine phosphorylation. Clone 15 was negative for
the expression of p65tpr-met. Size in kD was estimated using a mo-
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the empty pMT2 construct did not show any growth and
differentiating alterations (data not shown).
Effect of Heterologous h-met and h-HGF/SF Double 
Expression in C2 Cells
To determine whether the expression of an autocrine loop
for HGF/SF released from differentiation control could
result in a phenotype similar to that of p65tpr-met-expressing
C2 cells, we analyzed the properties of C2 cells double
transfected with the heterologous h-met and h-HGF/SF
coding sequences. The choice to use the human isoforms
allowed us to distinguish them from the endogenous ones
both at mRNA and protein levels. Stable transfection of
C2 cells was performed using pRK5-met, pPEB-HGF/SF,
and pRSV-neo constructs at a 5:5:1 ratio. From 40 clones
selected for G418 resistance, only two of them (clones 9
and 33) resulted positive for the synthesis of both h-met
and h-HGF/SF mRNAs. The remaining 38 G418-resistant
clones expressed h-met (eight clones), h-HGF/SF (nine
clones), or neither of them (data not shown). Subsequent
studies have revealed that, after three to five passages,
clone 9 did not express the h-met mRNA any more; the
loss of h-met transcript is probably the result of an unsta-
ble genomic integration of human DNA sequence. For this
reason, only clone 33 should be considered as a real dou-
ble transfectant (Fig. 9 A). As determined by Western blot
analysis, clone 33 expresses a highly tyrosine-phosphory-
lated form of h-met (Fig. 9 B). This is consistent with the
productive binding and activation by h-HGF/SF.
Cells from clone 33 show several alterations in the
growth properties, particularly in the ability to grow in soft
agar, whereas C2 clones expressing only h-met or h-HGF/
SF, as well as C2 parental cells, are not able to grow inde-
pendently from anchorage (data not shown).
The clone 33 was also tested for its differentiating po-
tential. Confluent cells were transferred in DME contain-
ing 10% HS. After a 48-h incubation in this medium, cells
were analyzed for the expression of MHC by indirect im-
munofluorescence staining. As shown in Fig. 9 C, clone 33
presents a significant inhibition of the differentiating pro-
cess, since few cells express myosin and most of them are
mononucleated and fusiform, similar to those observed in
p65tpr-met-expressing clones. In differentiation studies per-
formed by shifting to very low percentages of serum (0.5%
or 1% FCS), we have observed a partial restoration of the
differentiating capacity in clone 33 (data not shown). The
reacquiring of the differentiated phenotype can be ex-
plained by the prevention of HGF/SF processing in these
culture conditions, clearly indicating a lack of HGF/SF bio-
logical activity (Naka et al., 1992; Naldini et al., 1992, 1995).
In view of these data, although they refer to only one
h-met/h-HGF/SF–expressing clone, we can infer that a con-
stitutive autocrine loop for h-HGF/SF causes growth alter-
ations and myogenic inhibition.
Figure 7. Phenotypic appearance and differentiating properties
of p65tpr-met-expressing C2 clones. Micrographs of p65tpr-met highly
expressing cells (B) and C2 parental cells (A) cultured either in
growth or differentiation medium. The myogenic potential was
assessed by detecting myotube formation and by immunofluores-
cence staining for MHC in 48-h differentiation medium–exposed
cell cultures.
Figure 8. Decreased expression of muscle-regulatory genes in
p65tpr-met-expressing C2 clones. Total RNA from proliferating
(lanes  1) and differentiating (lanes 2, 3, and 4; 24-, 48-, and 72-h
postserum deprivation, respectively) cultures was hybridized with
the indicated probes. To estimate if equal amounts of RNA were
loaded, the same filter was probed with a constitutively expressed
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The single stable expression of h-met or h-HGF/SF in
C2 cells was not found to induce appreciable phenotypic
changes in proliferative conditions, indicating that a high
species-specificity of ligand–receptor interaction is required
to activate met signaling. Indeed, C2 clones selected for
expression of the human isoform of the receptor showed
consistent protein levels of h-met, which, in a different way
from the endogenous m-met, is weakly or not at all phos-
phorylated on tyrosine residues (Fig. 9 D). This is in accor-
dance with previous data obtained using mouse fibroblast
cells (Rong et al., 1992). Likewise, no substantial alter-
ations of muscle differentiation were observed in C2/h-met
and C2/h-HGF/SF clones in comparison with C2 parental
cells (data not shown).
Although we have had no particular problems in select-
ing C2 clones expressing p65tpr-met kinase, we presume that
the simultaneous expression of h-met and h-HGF/SF re-
sults in severe cell growth disturbances and is therefore
more restrictive for C2 myoblast survival. Two lines of evi-
dence support this hypothesis, with the first being the low
ratio of positive double transfectants as compared with
that of C2/h-met and C2/h-HGF/SF single transfectants.
Here it should be noted that the h-met/h-HGF/SF trans-
fection was repeated a second time yet without success
(from 30 clones selected, none were double positive). Sec-
ondly, cells of clone 33 are subject to cell death when cul-
tured in growth-restrictive conditions. Preliminary experi-
ments indicate that the observed cell death is to be
classified as apoptosis (data not shown).
Discussion
It is well known that muscle development is strongly influ-
enced by serum components, first of all by peptide growth
factors (for review see Florini and Magri, 1989; Florini et al.,
1991; Olson, 1992; Maione and Amati, 1996). The func-
tional relationships between growth factors and muscle
differentiation have been extensively investigated by using
in vitro cultured muscle cells and taking the advantage of
the myogenic process study in monitored conditions. Myo-
genesis in tissue culture is accompanied by a terminal and
irreversible withdrawal from cell cycle so that the postmi-
totic cells become committed to fusion and form multinu-
cleated myotubes (Nadal-Ginard, 1978). The morphologi-
Figure 9. Double ectopic ex-
pression of h-met and h-HGF/
SF is required for the consti-
tutive activation of h-met
kinase. (A) Northern blot
analysis of RNA expression
levels of h-met and h-HGF/SF
in clone 33 selected from C2
h-met/h-HGF/SF double trans-
fection.  Exogenous tran-
scripts are larger than endog-
enous ones. (B) The h-met
receptor expressed by clone
33 is phosphorylated on ty-
rosine residues. Cells were
lysed at two different culture
passages and immunoprecip-
itated with anti–human met
antibodies. Proteins were re-
solved by 8% reducing SDS-
PAGE and immunoblotted
with anti–human met ( a -h-
met) or anti-phosphotyro-
sine (a-PTyr) antibodies. (C)
Phase-contrast and anti-MHC
immunofluorescence micro-
graphs of clone 33 cells ex-
posed for 48 h in differentia-
tion medium containing 10%
HS. (D) Cell lysates from C2
parental cells and three sin-
gle h-met–expressing C2 (C2/
h-met) clones were immuno-
precipitated with anti–murine
met antiserum (C2 cells) or
with anti-human met anti-
serum (C2/h-met clones), re-
spectively. The immunocom-
plexes were resolved by 8%
reducing SDS-PAGE and
immunoblotted with anti–human (a-h-met) or anti-phosphotyrosine mAbs (a-PTyr). The almost undetectable tyrosine phosphorylation
exhibited by h-met in comparison with the endogenous receptor suggests that it is not efficiently activated by murine HGF/SF.Anastasi et al. Coexpression of met and Its Ligand in Myoblast Cells 1065
cal events in muscle differentiation are associated with the
expression of an array of muscle-specific gene products,
especially structural proteins of the contractile apparatus.
In this context, the local concentration of growth factors
(of own production or added exogenously to the culture
medium) results in being critical for maintaining cells as
proliferating myoblasts or inducing them to acquire the dif-
ferentiated phenotype. Until now, much of the work done
was centered on distinct growth factors such as FGF, TGF-b,
and the somatomedins (insulin, insulin-like growth factor-1
[IGF-1], and insulin-like growth factor-2 [IGF-2]) (Florini
and Magri, 1989; Florini et al., 1991; Olson, 1992; Maione
and Amati, 1996). All of them have been recognized to ex-
ert a key function in the control of in vitro, and presum-
ably also in vivo, muscle differentiation. Nevertheless, it
cannot be excluded that additional factors exist that con-
tribute to the regulatory pathways governing the myogenic
process.
In the present work we have addressed the question of
whether HGF/SF, a pleiotropic protein able to elicit multi-
ple biological responses (for review see Goldberg and
Rosen, 1993), could play a role in the differentiation of the
myogenic mouse C2 cell line.
We have shown that C2 myoblasts express both HGF/
SF and its receptor, met tyrosine kinase. Despite the fact
that HGF/SF has been considered essentially as a para-
crine factor secreted by mesenchymal cells and effective on
epithelial cells, some examples of natural autocrine cells
for HGF/SF have been described (Adams et al., 1991; Rong
et al., 1992, 1993; Tsao et al., 1993; Ferracini et al., 1995;
Woolf et al., 1995; Maier et al., 1996). We show that an au-
tocrine loop for HGF/SF is present and active in C2 cells
since the high levels of tyrosine phosphorylation exhibited
by  met receptor are dependent from the endogenously
produced ligand. Further experiments have produced evi-
dence of the coexpression of HGF/SF and its related re-
ceptor also in another myogenic cell line and in mouse pri-
mary satellite cells.
Different studies indicate that HGF/SF can exert an im-
portant function in muscle development. It has been shown
that met and HGF/SF transcripts are present in muscle for-
mation sites during mouse embryogenesis (Sonnenberg
et al., 1993). Bladt et al. (1995) reported that mice ho-
mozygous for a null mutation of the met locus fail to form
muscles in the limb anlage, in the diaphragm, and at the tip
of the tongue, because of the inability of myogenic precur-
sor cells to migrate from the somites to these sites. A detailed
work by Yang et al. (1996) confirms that, in Pax 3–deficient
mice, the loss of met gene expression in somitic myogenic
precursors correlates with the lack of limb bud coloniza-
tion. Similar results were obtained by Maina et al. (1996)
by using mice carrying met receptor variants that are de-
fective in the transduction of HGF/SF signal. In addition,
they reveal a novel role of met kinase also in promoting
the proliferation of fetal myoblasts just before the forma-
tion of the secondary fibers during the late stages of mus-
cle development. However, no clear hint about a putative
autocrine condition for HGF/SF in myogenic cell lineage
was given in these works. Rather, a general paracrine con-
trol by this growth factor was postulated. Our results ap-
pear in disagreement with this interpretation since we
have observed an autocrine loop for HGF/SF both in C2
myoblasts and in mouse primary satellite cells. Since C2
myoblasts were also derived from satellite cells (Yaffe and
Saxel, 1977), it can be hypothesized that the autocrine
loop for HGF/SF could represent an intrinsic characteris-
tic of satellite cells. According to this assumption, it is ex-
pected that the HGF/SF autocrine loop would become es-
tablished only when satellite cells are induced to replicate
and migrate to where damaged muscle fibers must be re-
placed. In this regard, a study by Jennische et al. (1993)
points out an induction of HGF/SF gene expression in rat
skeletal-regenerating muscle after ischemic injury. A sec-
ond element of concordance is that HGF/SF stimulates the
growth of satellite cells otherwise quiescent (Allen et al.,
1995). It should not be completely excluded that the coex-
pression of met and HGF/SF genes could occur in the
somitic precursors and in other cells belonging to the myo-
genic lineage without preventing them from responding
also to an external HGF/SF gradient. The finding that an
inappropriate expression of HGF/SF in transgenic mice
causes ectopic muscle formation in the central nervous
system (Takayama et al., 1996) strengthens the view that a
spatially and temporally regulated HGF/SF signaling would
be required for a proper myogenic process, during both
embryogenesis and muscle regeneration. Work in this field
will be extremely informative for better understanding the
complexity of HGF/SF action in muscle development.
We have shown that the expression of HGF/SF and met
genes is subordinated to the proliferative state of myoblast
cells since a transcriptional decline for both of them was
consistently observed after induction of differentiation.
The modulation of genes encoding for growth factors and
growth factor receptors seems to be quite a common strat-
egy adopted by muscle cells when they enter the differen-
tiating pathway (Florini and Magri, 1989; Florini et al.,
1991; Olson, 1992). For example, the endogenous expres-
sion of FGF and TGF-b, as well as that of their cognate re-
ceptors, is downregulated during myogenesis (Ewton et al.,
1988; Olwin and Hauschka, 1988; Hu and Olson, 1990:
Lafyatis et al., 1991; Moore et al., 1991).
The disappearance of growth factor receptors with the
onset of differentiation is important in ensuring an irre-
versible withdrawal from cell cycle and, consequently, a
stable expression of muscle-specific phenotype. In fact, fu-
sion-defective muscle cells differentiate with neither ter-
minal commitment nor receptor decline in such a way that
they can reverse muscle phenotype after growth factor ex-
posure (Hu and Olson, 1990). However, existing data sug-
gest that the loss of responsiveness to growth factors oc-
curs also at a postreceptor level (Maione and Amati, 1996).
An opposite kind of regulation has been evidenced for the
myogenic stimulators IGF-1, IGF-2, and their related re-
ceptors, whose expression increases coordinately in differ-
entiating cells (Tollefsen et al., 1989a,b).
The observed HGF/SF and met gene downregulation
suggests a functional shut-off in the autocrine stimulation
by HGF/SF during C2 myogenic differentiation. Our data
are in agreement with the previous observation that in ro-
dents HGF/SF and met receptor are expressed in skeletal
muscle tissue during embryonic development and in the
first days after birth, while the levels of the relative tran-
scripts are weak or not detectable in adult skeletal muscle
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HGF/SF could generate a signal interfering with the dif-
ferentiating program, just like FGF and TGF-b. Research
is in progress to determine the possible role of myogenic
factors in the downregulation of both met and HGF/SF
during C2 differentiation.
We have found a similar differentiation-dependent down-
regulation of HGF/SF-met system in other met-HGF/SF
coexpressing cells, C3H-10T1/2 mouse fibroblasts con-
verted to myoblasts by stably expressed MyoD. This find-
ing further supports the incompatibility between met ki-
nase signaling and the differentiating program.
The transcriptional downregulation of HGF/SF and met
genes during muscle differentiation allows us to think that
a premature met kinase signaling interruption could result
in a major propension of cells to differentiate. However,
our attempts to force C2 myoblasts to enter the differenti-
ating pathway by cultivating them in growth medium sup-
plemented with anti-HGF/SF neutralizing antibodies were
not successful; in fact, no sign of precocious myogenesis
was detected (data not shown). It is possible that the high
levels of HGF/SF produced by C2 cells would make the in-
terruption of the autocrine stimulation by the neutralizing
antibodies very difficult, at least in the conditions we used.
Furthermore, met kinase inactivation could be necessary,
but not by itself sufficient, to permit muscle differentiation
since additional inhibitory constraints would continue to
function in these conditions.
Nevertheless, strong evidence for a negative effect of met
kinase signaling on myogenic differentiation comes from
the characterization of C2 clones expressing the constitu-
tively activated p65tpr-met fusion protein. As determined by
immunofluorescence staining, these clones are defective
for the synthesis of muscle-specific structural proteins
(MHC) and myotube formation. The extent of this myo-
genesis inhibition corresponds with the expression levels
of p65tpr-met.
A reduced expression of different myogenic helix-loop-
helix transcription factors, such as MyoD and myogenin,
was also detected in these clones. Once again, the p65tpr-met
highly expressing clones exhibit the most extreme pheno-
type with a complete failure in myogenin gene activation
and with the silencing of MyoD gene expression. A nega-
tive regulation of both gene expression and functional ac-
tivity of MyoD has been already reported for FGF and
TGF-b (Vaidya et al., 1989). The mechanisms by which
the activation of the growth factor pathways interfere with
the myogenic program are under extensive investigation
(for reviews see Olson, 1992; Maione and Amati, 1996).
In addition, we have shown that the activity of p65tpr-met
kinase induces remarkable changes in cell morphology.
Particularly in p65tpr-met highly expressing clones, cells ap-
pear spindle-shaped and refractile, denoting a poor adher-
ence to substrate, witnessed also by a major sensitivity to
trypsinization. The presence of a network of threadlike cy-
toplasmic extensions is reminiscent of the scattered ap-
pearance of epithelial cells upon HGF/SF stimulation, indi-
cating that p65tpr-met signaling triggers an increased motogenic
response.
Attempting to obtain further insight into the role of
HGF/SF in C2 differentiation and to overcome the differ-
entiation-dependent decrease of HGF/SF and met endoge-
nous genes, we have also studied the effects of an ectopic
constitutive expression of the human isoforms of HGF/SF
and of its cognate receptor in C2 myoblasts.
Clones selected for the single expression of h-met or
h-HGF/SF do not exhibit significant phenotypic alterations
compared with those of the parental cell line, although
they produce detectable quantities of each product. From
the results it may be inferred that a species-specific corre-
spondence between the ligand and its related receptor is
required to create an effective autocrine loop for h-HGF/
SF in C2 myoblasts. This is noteworthy if we consider the
high degree of homology between murine and human
HGF/SF proteins, which is .90% (Liu et al., 1993). How-
ever, a low binding affinity of HGF/SF to heterospecific
receptor molecules has been originally reported by Rong
et al. (1992) to explain the tumorigenicity induced by met
proto-oncogene in a murine fibroblast cell line. The find-
ing that in C2/h-met clones the human isoform of the re-
ceptor is weakly or not at all tyrosine-phosphorylated is in
line with this high species-specificity, since murine HGF/SF
is not efficient in activating h-met.
On the other hand, the establishment of an autocrine
loop for h-HGF/SF through its coexpression with h-met in
C2 cells results in soft agar growth ability and in a simulta-
neous myogenic inhibition, just as for p65tpr-met-expressing
clones. In this case, h-met exhibits a quantitative tyrosine
phosphorylation, indicating a full activation by h-HGF/SF.
In light of these observations, we believe that a met re-
ceptor stably activated through an autocrine HGF/SF
stimulation could be equivalent to the expression of tpr-
met kinase, despite the fact that p65tpr-met has a cytoplasmic
localization and a constitutive kinase activity independent
from HGF/SF. Yet some differences must be present, since
we were able to select only one C2 clone expressing simul-
taneously h-met and h-HGF/SF from two distinct transfec-
tion assays. This difficulty was further confirmed by the
loss of one human product in a second clone and by the cell
death observed when cells of clone 33 were transferred to
differentiation medium. It appears therefore that the estab-
lishment of a species-specific autocrine loop for h-HGF/SF,
released from differentiation-dependent control, has a ma-
jor negative action on C2 myoblasts.
In sum, our results support the notion that HGF/SF plays a
role in the motogenic and growth properties of myogenic
cells through an autocrine loop that needs to be downregu-
lated during differentiation, since the constitutive activation
of met kinase is incompatible with myogenesis.
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